Luncheon symposium & Poster presentation
|
1 |
ÀýÁ¦°¡ ºÒ°¡´ÉÇÑ ´ã°ü¾Ï¿¡¼ S-1 °æ±¸Ç×¾ÏÈÇпä¹ý°ú º´ÇàÇÑ CyberKnife radiosurgery: Áõ·Ê º¸°í |
¹ÚÁø¼®(ÀÎÇÏ´ë) |
|
2 |
±¤¿ªµ¿ Ä¡·á·Î ÁÁÀº ¹ÝÀÀÀ» º¸ÀÎ ±¹¼ÒÀû ÁøÇ༺ °£¹®ºÎ¾Ï ȯÀÚ 1¿¹ |
Àü¼º°ï(¼øõÇâ´ë) |
|
3 |
Chemotherapy in Patients with Biliary Tract Cancer: A Single-Institution Experience |
ÃÖÄ¡ÈÆ(ÇѸ²´ë) |
|
4 |
Rupture of CBD in Patient with Metastatic Biliary Obstruction |
À±ÁöÀº(ÇѸ²´ë) |
|
5 |
°£µ¿¸Æ ÁÖÀÔ Ç×¾Ï ÈÇÐ ¿ä¹ýÀ¸·Î ¿ÏÀü °üÇØµÈ ´ã³¶¾Ï 1¿¹ |
±èµ¿Èñ(¿µ³²´ë) |
|
6 |
An early phase II trial of S-1 and concurrent chemoradiotherapy in patients with locally advanced biliary tract cancer |
¼ÁÖÈñ(¿¬¼¼´ë) |
|
7 |
´ëÀå ¹Ì¼Ò ¿ëÁ¾¿¡¼ ¹ß°ßµÈ ¿ø¹ß¼º ¹ÝÁö¼¼Æ÷¾ÏÁ¾ 1¿¹ |
¿ÀÈñÁÖ(¿µ³²´ë) |
|
8 |
Rectal cancer and nasopharyngeal metastasis |
±è»óÈñ(°¡Å縯´ë) |
|
9 |
Dual self-expandable metal stent »ðÀÔÀ¸·Î Áõ»ó È£ÀüµÈ ´©°øÀ» µ¿¹ÝÇÑ ¾Ç¼º ´ëÀåÇùÂø 1·Ê |
¼À¯½Â(¼øõÇâ´ë) |
|
10 |
Á÷Àå¾Ï °£ÀüÀÌ·Î Ç×¾ÏÄ¡·á Áß ¹ß»ýÇÑ ÁÖÆóÆ÷ÀÚÃæ(pneumocystis carinii) Æó·Å 1¿¹ |
½ÅÀº°æ |
|
11 |
Colitic cancer ¿¹¹æÀ» À§ÇÑ InfliximabÀÇ step down therapy strategy |
±èºÀȯ(ºÐ´çÁ¦»ýº´¿ø) |
|
12 |
Á÷Àå¿¡ ¹ß»ýÇÑ ¿ø¹ß¼º ¹Ì¸¸¼º BÇü ´ë¼¼Æ÷ ¸²ÇÁÁ¾ 2¿¹ |
±èµ¿Èñ(¿µ³²´ë) |
|
13 |
°£ ÀüÀ̸¦ µ¿¹ÝÇÑ ½ÄµµÀÇ ±âÀú¼¼Æ÷¾ç ÆíÆò¼¼Æ÷¾Ï 1¿¹ |
ÀÌÀÀ°©(°æºÏ´ë) |
|
14 |
Complete Response in a Case of Advanced Esophageal Cancer Treated by Mono-Chemotherapy of TS-1. |
±èµ¿¿í(ºÎ»ê´ë) |
|
15 |
ÀþÀº ¼ºÀο¡¼ ¹ß»ýÇÑ ¿ø¹ß¼º °øÀå ¼±¾ÏÁ¾ 1¿¹ |
¹ÚÀçÀº(°¡Å縯´ë) |
|
16 |
A case of Primary mesenteric root mesothelioma, mimicking sclerosing mesenteritis. |
À±¿µÈÆ(Á¦ÁÖÇѶ󺴿ø) |
|
17 |
¹é¼¿¡¼ methotrexate¿¡ ÀÇÇÏ¿© À¯¹ßµÈ Àå±â¹«°Ô ¹× üÁß º¯È¿Í Àå³»¼¼±ÕÀüÀ§¿¡ ´ëÇÑ ´Ü±â°£ ±Ý½ÄÀÇ È¿°ú |
±èÁ¤¿í(Áß¾Ó´ë) |
|
18 |
°£¿ÜÀüÀ̸¦ µ¿¹ÝÇÑ ÁøÇ༺ °£¼¼Æ÷¾Ï¿¡¼ °æµ¿¸ÆÈÇлöÀü¼ú°ú °í°µµÁý¼ÓÃÊÀ½ÆÄ ÀÀ°í¼ú º´ÇÕÄ¡·á 1·Ê |
¿ì¼º¿ë(°¡Å縯´ë) |
|
19 |
½ºÅÙÆ® »ðÀÔ ¹× Ç׾Ͽä¹ý ÈÄ ±ÙÄ¡Àû ÀýÁ¦¼úÀ» ½ÃÇàÇß´ø Æó¼â¼º ±¹¼Ò ħ¹ü °øÀå ¼±¾Ï 1¿¹ |
±èÇü±â(¼øõÇâ´ë) |
|
20 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer |
±èÀ±Àç(¿¬¼¼´ë) |
|
21 |
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer |
±èÈñ¸¸(¿¬¼¼´ë) |
|
22
|
Weekly Full-dose Gemcitabine and Single-dose Cisplatin with Concurrent Radiotherapy in Patients with Locally Advanced Pancreatic Cancer |
È«¼ºÇÊ(¿¬¼¼´ë) |
|
23
|
Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment in Locally Advanced or Metastatic Pancreatic Cancer |
¿øÁ¾Áø(µ¿¾Æ´ë) |
|
24 |
Efficacy of Erlotinib plus Gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer |
¹Ú¼¼¹Ì(¿¬¼¼´ë) |
|
25 |
FOLFOX4 as a rescue chemotherapy in gemcitabine based chemotherapy refractory pancreatic cancer |
Á¤ÁÖ¿ø(¿¬¼¼´ë) |
|
26 |
À§¾Ï ¼¼Æ÷ÁÖ¿¡¼ AstaxanthinÀÇ Ç×¾Ï È¿°ú¿¡ °üÇÑ ¿¬±¸ |
À̹üÀç(°í·Á´ë) |
|
27 |
À§ ÀüÁ¤ºÎ¿¡¼ ¹ß»ýÇÑ À§¼±¾Ï°ú µ¿¹ÝµÈ ½Å°æ³»ºÐºñ¾ÏÀÇ È¥ÇÕÁ¾¾ç 1¿¹ |
À̼ҿµ(°¡Å縯´ë) |
|
28 |
ÁøÇ༺ À§¾ÏÀÇ ±ÙÄ¡Àû À§ÀýÁ¦¼ú ÈÄ Epirubicin , Cisplatin , 5-FluorouracilÀÇ º¹ÇÕ º¸Á¶Ç׾Ͽä¹ýÀÇ Ä¡·áÈ¿°ú |
¿øÁ¾Áø(µ¿¾Æ´ë) |
|
29 |
Ç×¾Ï Ä¡·áÁßÀÎ À§¾Ï ȯÀÚ¿¡¼ ÇǺÎÀüÀÌ·Î ¿ÀÀÎµÈ ½ºÆĸ£°¡´®Áõ |
ÀÌÁö¼÷(°í½Å´ë) |
|
30 |
ÁøÇ༺À§¾ÏȯÀÚ¿¡¼ Ç׾Ͽä¹ý ¹ÝÀÀÀ» ¿¹ÃøÇϱâ À§ÇÑ ¾Æµ¥³ë½Å 3Àλê/Ç×¾ÏÁ¦¹ÝÀÀ°Ë»ç(ATP-CRA)ÀÇ »ç¿ë |
±èÈ«Á¤(¿¬¼¼´ë) |
|
31 |
À§ ¸²ÇÁÁ¾À¸·Î ¿ÀÀÎµÈ ¿ø¹ß¼º À§ ¼Ò¼¼Æ÷¾Ï |
À¯½Âö(°¡Å縯´ë) |
|
32 |
°£¼¼Æ÷¾Ï°ú À§½ÄµµÁ¢ÇպΠ¼±¾Ï ±×¸®°í ÇÏÀεξÏÀ» µ¿¹ÝÇÑ »ïÁß¾Ï 1¿¹ |
¹ÚÀºÈ£(°í½Å´ë) |
|
33 |
A pilot study of preoperative concurrent chemoradiotherapy with S-1 and cisplatin in locally advanced gastric cancer |
Á¤À±¼÷(¿¬¼¼´ë) |